Clinical Trials
Study purpose Prospective observational trial to benchmark the performance of the CleoDX Pre-Surgical Triage Test against CA125 & ultrasound to indicate risk of ovarian malignancy.

Cleo Diagnostics is a biotechnology company whose pre-surgical serum test, ordered through pathology providers, measures biomarkers for ovarian malignancy risk.
cleodx.comCrawled Nov 8, 2026
Study purpose Prospective observational trial to benchmark the performance of the CleoDX Pre-Surgical Triage Test against CA125 & ultrasound to indicate risk of ovarian malignancy.
Cleo’s pre-surgical triage test is a new blood test to help doctors more accurately predict the chance that an adnexal mass might be an ovarian cancer, or whether it is a far more common benign growth.
Ovarian cancers often present late with vague symptoms, requiring clinicians to assess malignancy risk in patients with adnexal masses.
The page explains how Cleo Diagnostics is developing a blood test for early ovarian cancer diagnosis.
As a part of CLEO’s U.S. market access program, the Company will partner with U.S.-based CRO, Lindus Health, appointing it to manage the successful execution of its ovarian cancer U.S. clinical trials.
The U.S. represents CLEO’s largest market opportunity for its ovarian cancer blood test and is the focus for initial regulatory approval through the Food and Drug Administration (FDA).
Cleo Diagnostics Limited published a milestone article on its blood test for accurate, early ovarian cancer detection.
Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to provide the market with an update on activities in the June 2024 quarter as it develops its simple and accurate blood test for the early detection of ovarian cancer.
Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to provide the market with an update on activities in the March 2024 quarter as it develops its simple and accurate blood test for the early detection of ovarian cancer.
Cleo Diagnostics Limited released further data on its ovarian cancer triage test.
Cleo Diagnostics Limited will begin analytical validation of its Pre-Surgical Ovarian Cancer Test after receiving commercial kits from Bio-Techne.
Cleo Diagnostics Limited signed a Statement of Work with Asuragen to validate its Pre-Surgical Ovarian Cancer Test.
Dr Richard Allman - Chief Executive Officer and Executive Director
PhD (Molecular Biology) from Monash University Australia
PhD (Microbiology) from The University of Wales
Chief Executive Officer and Executive Director PhD (Microbiology) from The University of Wales
Chief Executive Officer and Executive Director PhD Microbiology) from The University of Wales
The page lists qualifications and roles for a gynaecological oncology specialist at Monash Health.
Cleo Diagnostics is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer.
Level 2, 480 Collins Street Melbourne Victoria 3000
CLEO is developing a multi-marker blood test for ovarian cancer screening. The company has begun prototype development of its diagnostic tool, leveraging a blood-based approach to detect early signs of the disease. This initiative aims to improve early detection methods in oncology.
CLEO partners with Asuragen, a CLIA-certified U.S. laboratory, to support its pivotal clinical validation program for a pre-surgical ovarian cancer test. The collaboration aims to advance regulatory approval efforts by leveraging Asuragen’s accredited facilities and expertise in clinical diagnostics. This step follows CLEO’s focus on improving early detection methods for ovarian cancer.
CLEO completes collection of 514 blood samples for its pivotal U.S. clinical trial, advancing progress toward an FDA submission. The samples support development of CLEO’s Pre-Surgical Ovarian Cancer Test, a diagnostic tool aimed at improving early detection. This milestone marks a critical step in the company’s regulatory pathway.
CLEO expands its biomarker panel from five to eight markers to enhance analytical performance, reproducibility, and commercial scalability before submitting its FDA 510(k) application. The optimizations aim to strengthen the panel’s reliability for regulatory approval and market readiness. The company now focuses on finalizing preparations for its submission to the U.S. Food and Drug Administration.
CLEO secures **$5 million in funding** through a placement at **$0.60 per share** to expand into the **U.S. market** and accelerate the development of its **screening test products**. The capital will support scaling operations and advancing diagnostic solutions for broader accessibility.